Immune Thrombocytopenia: Pathophysiologic and Clinical Update

 

 Buy Article Permissions and Reprints

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by both reduced platelet survival and suppression of megakaryocyte and platelet development. It can either be primary or secondary to other autoimmune disorders, infections, vaccines, lymphoproliferative disorders, and drugs. Antibodies reacting against platelet glycoproteins are typical of ITP; these antibodies can mediate destruction of platelets by the monocyte–macrophage system as well as suppress megakaryocyte proliferation and maturation. Abnormalities of cell-mediated immunity are known to contribute to the pathologic process. Like many other autoimmune diseases, ITP has a T helper cell type 1 bias and a reduced activity of T-regulatory cells. Cytotoxic T cells may directly lyse platelets and possibly suppress megakaryopoiesis. Recent studies suggest that mesenchymal stem cells are dysfunctional in ITP and may contribute to an aberrant amplification of the autoimmune response. Significant advances in the treatment of chronic ITP have been witnessed in the past decade, first with the introduction of rituximab and more recently with the thrombopoietin-receptor agonists. While splenectomy is still considered the gold standard in this setting, effective medical therapy is now available for patients in whom surgery is not an option.

• References

• 1 Rodeghiero F, Stasi R, Gernsheimer T , et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11) 2386-2393
  CrossrefPubMedGoogle Scholar
• 2 Stratton JR, Ballem PJ, Gernsheimer T, Cerqueira M, Slichter SJ. Platelet destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of indium-111-labeled autologous platelets. J Nucl Med 1989; 30 (5) 629-637
  PubMedGoogle Scholar
• 3 Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999; 106 (4) 430-434
  CrossrefPubMedGoogle Scholar
• 4 Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38 (1) 1-10
  PubMedGoogle Scholar
• 5 Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci 1965; 124 (2) 499-542
  PubMedGoogle Scholar
• 6 Sukati H, Watson HG, Urbaniak SJ, Barker RN. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood 2007; 109 (10) 4528-4538
  CrossrefPubMedGoogle Scholar
• 7 McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003; 1 (3) 485-491
  CrossrefPubMedGoogle Scholar
• 8 Kuwana M, Kaburaki J, Kitasato H , et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001; 98 (1) 130-139
  CrossrefPubMedGoogle Scholar
• 9 McMillan R, Lopez-Dee J, Bowditch R. Clonal restriction of platelet-associated anti-GPIIb/IIIa autoantibodies in patients with chronic ITP. Thromb Haemost 2001; 85 (5) 821-823
  PubMedGoogle Scholar
• 10 Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Evidence for a light chain restriction of glycoprotein Ib/IX and IIb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1995; 90 (1) 175-179
  CrossrefPubMedGoogle Scholar
• 11 McMillan R, Longmire RL, Yelenosky R, Smith RS, Craddock CG. Immunoglobulin synthesis in vitro by splenic tissue in idiopathic thrombocytopenic purpura. N Engl J Med 1972; 286 (13) 681-684
  CrossrefPubMedGoogle Scholar
• 12 Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168 (7) 3675-3682
  PubMedGoogle Scholar
• 13 Siegel RS, Rae JL, Barth S , et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989; 30 (4) 206-212
  CrossrefPubMedGoogle Scholar
• 14 Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999; 93 (6) 1951-1958
  PubMedGoogle Scholar
• 15 Semple JW, Milev Y, Cosgrave D , et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87 (10) 4245-4254
  PubMedGoogle Scholar
• 16 Stasi R, Del Poeta G, Stipa E , et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110 (8) 2924-2930
  CrossrefPubMedGoogle Scholar
• 17 Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88 (1) 194-201
  PubMedGoogle Scholar
• 18 Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol 1996; 56 (1–2) 72-77
  PubMedGoogle Scholar
• 19 Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998; 102 (7) 1393-1402
  CrossrefPubMedGoogle Scholar
• 20 Filion MC, Proulx C, Bradley AJ , et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood 1996; 88 (6) 2144-2150
  PubMedGoogle Scholar
• 21 Fogarty PF, Rick ME, Zeng W, Risitano AM, Dunbar CE, Bussel JB. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol 2003; 133 (3) 461-466
  CrossrefPubMedGoogle Scholar
• 22 Olsson B, Andersson PO, Jernås M , et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9 (9) 1123-1124
  CrossrefPubMedGoogle Scholar
• 23 Liu B, Zhao H, Poon MC , et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78 (2) 139-143
  PubMedGoogle Scholar
• 24 Olsson B, Andersson PO, Jacobsson S, Carlsson L, Wadenvik H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005; 93 (1) 139-144
  PubMedGoogle Scholar
• 25 Catani L, Fagioli ME, Tazzari PL , et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006; 34 (7) 879-887
  CrossrefPubMedGoogle Scholar
• 26 Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 2009; 7 (2) 322-329
  PubMedGoogle Scholar
• 27 Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am 2009; 23 (6) 1275-1297
  CrossrefPubMedGoogle Scholar
• 28 Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46 (1, Suppl 2) S2-S14
  CrossrefPubMedGoogle Scholar
• 29 Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009; 113 (17) 4086-4093
  CrossrefPubMedGoogle Scholar
• 30 Nardi MA, Liu LX, Karpatkin S. GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia. Proc Natl Acad Sci U S A 1997; 94 (14) 7589-7594
  CrossrefPubMedGoogle Scholar
• 31 Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 2005; 106 (2) 572-576
  CrossrefPubMedGoogle Scholar
• 32 Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001; 106 (5) 551-561
  CrossrefPubMedGoogle Scholar
• 33 Ballem PJ, Belzberg A, Devine DV , et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327 (25) 1779-1784
  CrossrefPubMedGoogle Scholar
• 34 Zucker-Franklin D, Seremetis S, Zheng ZY. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood 1990; 75 (10) 1920-1923
  PubMedGoogle Scholar
• 35 Stasi R, Sarpatwari A, Segal JB , et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113 (6) 1231-1240
  CrossrefPubMedGoogle Scholar
• 36 Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2: 8
  CrossrefPubMedGoogle Scholar
• 37 Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105 (4) 1815-1822
  CrossrefPubMedGoogle Scholar
• 38 Pérez-Simón JA, Tabera S, Sarasquete ME , et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009; 11 (6) 698-705
  CrossrefPubMedGoogle Scholar
• 39 Fang B, Mai L, Li N, Song Y. Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev 2012; 21 (3) 497-502
  CrossrefPubMedGoogle Scholar
• 40 Norgaard M, Jensen AO, Engebjerg MC , et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 2011; 117 (13) 3514-3520
  CrossrefPubMedGoogle Scholar
• 41 Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160 (11) 1630-1638
  CrossrefPubMedGoogle Scholar
• 42 Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97 (9) 2549-2554
  CrossrefPubMedGoogle Scholar
• 43 George JN, Woolf SH, Raskob GE , et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88 (1) 3-40
  PubMedGoogle Scholar
• 44 Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79 (4) 504-522
  CrossrefPubMedGoogle Scholar
• 45 Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106 (7) 2244-2251
  CrossrefPubMedGoogle Scholar
• 46 George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006; 4 (8) 1664-1672
  CrossrefPubMedGoogle Scholar
• 47 Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006; 43 (3 Suppl 5) S3-10 ; discussion S18–S19
  PubMedGoogle Scholar
• 48 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA ; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
  CrossrefPubMedGoogle Scholar
• 49 Cheng Y, Wong RS, Soo YO , et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349 (9) 831-836
  CrossrefPubMedGoogle Scholar
• 50 Mazzucconi MG, Fazi P, Bernasconi S , et al; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109 (4) 1401-1407
  CrossrefPubMedGoogle Scholar
• 51 Bae SH, Ryoo H-M, Lee WS , et al. High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. ASH Annual Meeting Abstracts 2010; 116 (21) 3687
  PubMedGoogle Scholar
• 52 Gruppo Italiano Malattie EMatologiche dell'Adulto. Prednisone or dexamethasone in treating patients with newly diagnosed, previously untreated primary immune thrombocytopenic purpura. Available at: http://clinicaltrials.gov/ct2/show/NCT00657410 . Accessed on 18 February 2012.
  Google Scholar
• 53 Scaradavou A, Woo B, Woloski BM , et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89 (8) 2689-2700
  PubMedGoogle Scholar
• 54 Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112 (4) 1076-1078
  CrossrefPubMedGoogle Scholar
• 55 Meyer O, Kiesewetter H, Hermsen M , et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer 2006; 47 (5, Suppl) 721-722
  CrossrefPubMedGoogle Scholar
• 56 Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106 (5) 1532-1537
  CrossrefPubMedGoogle Scholar
• 57 Ramachandran P, Li D, Muller C , et al. Potential identification of high risk populations for acute hemolytic reactions following Rh0 (D) immune globulin. ASH Annual Meeting Abstracts 2010; 116 (21) 3685
  PubMedGoogle Scholar
• 58 Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80 (6) 1051-1054
  CrossrefPubMedGoogle Scholar
• 59 Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost 2008; 100 (5) 762-765
  PubMedGoogle Scholar
• 60 Culić S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120 (5) 909-910
  CrossrefPubMedGoogle Scholar
• 61 Barnes C, Blanchette V, Canning P, Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005; 15 (2) 145-150
  CrossrefPubMedGoogle Scholar
• 62 Busani S, Marietta M, Pasetto A, Girardis M. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005; 93 (2) 381-382
  PubMedGoogle Scholar
• 63 Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006; 81 (3) 218-219
  PubMedGoogle Scholar
• 64 Wróbel G, Dobaczewski G, Patkowski D, Sokół A, Grotthus E. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006; 47 (5, Suppl) 729-730
  CrossrefPubMedGoogle Scholar
• 65 Salama A, Rieke M, Kiesewetter H, von Depka M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol 2009; 88 (1) 11-15
  CrossrefPubMedGoogle Scholar
• 66 Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104 (9) 2623-2634
  CrossrefPubMedGoogle Scholar
• 67 Vianelli N, Galli M, de Vivo A , et al; Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90 (1) 72-77
  PubMedGoogle Scholar
• 68 Najean Y, Rain JD, Billotey C. The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 1997; 97 (3) 547-550
  CrossrefPubMedGoogle Scholar
• 69 Sarpatwari A, Provan D, Erqou S, Sobnack R, David Tai FW, Newland AC. Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol 2010; 151 (5) 477-487
  CrossrefPubMedGoogle Scholar
• 70 Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122 (3) 187-188
  PubMedGoogle Scholar
• 71 Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99 (1) 4-13
  PubMedGoogle Scholar
• 72 Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98 (4) 952-957
  CrossrefPubMedGoogle Scholar
• 73 Arnold DM, Dentali F, Crowther MA , et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146 (1) 25-33
  CrossrefPubMedGoogle Scholar
• 74 Patel VL, Mahevas M, Stasi R , et al. Long-term outcome following B-cell depletion therapy with rituximab in children and adults with immune thrombocytopenia (ITP). ASH Annual Meeting Abstracts 2010; 116 (21) 72
  PubMedGoogle Scholar
• 75 Godeau B, Fain O, Porcher R , et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study. Blood 2006; 108 (11) Abstract #478
  PubMedGoogle Scholar
• 76 Schipperus M, Fijnheer R. New therapeutic options for immune thrombocytopenia. Neth J Med 2011; 69 (1) 480-485
  PubMedGoogle Scholar
• 77 Willis F, Marsh JC, Bevan DH , et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114 (4) 891-898
  CrossrefPubMedGoogle Scholar
• 78 Cosgriff TM, Black ML, Stein III W. Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin. Am J Hematol 1998; 57 (1) 85-86
  CrossrefPubMedGoogle Scholar
• 79 Bernard T, Kelsey SM, Macey MG, Cahill MR, Howe T, Newland AC. Protein-A-column plasma immunoadsorption in refractory autoimmune neutropenia and thrombocytopenia. Lancet 1993; 341 (8861) 1657-1658
  CrossrefPubMedGoogle Scholar
• 80 Huhn RD, Fogarty PF, Nakamura R , et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101 (1) 71-77
  CrossrefPubMedGoogle Scholar
• 81 Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76 (6) 628-638
  CrossrefPubMedGoogle Scholar
• 82 Erickson-Miller CL, DeLorme E, Tian SS , et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33 (1) 85-93
  CrossrefPubMedGoogle Scholar
• 83 Kuter DJ, Bussel JB, Lyons RM , et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371 (9610) 395-403
  CrossrefPubMedGoogle Scholar
• 84 Kuter DJ, Rummel M, Boccia R , et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363 (20) 1889-1899
  CrossrefPubMedGoogle Scholar
• 85 Kuter DJ, Bussel JB, Newland A , et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. ASH Annual Meeting Abstracts 2010; 116 (21) 68
  PubMedGoogle Scholar
• 86 Bussel JB, Provan D, Shamsi T , et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373 (9664) 641-648
  CrossrefPubMedGoogle Scholar
• 87 Cheng G, Saleh MN, Marcher C , et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377 (9763) 393-402
  CrossrefPubMedGoogle Scholar
• 88 Stasi R, Cheng G, Saleh MN , et al. Durable and overall platelet responses in patients with chronic idiopathic thrombocytopenic purpura (ITP) during long-term treatment with oral eltrombopag by splenectomy status: the RAISE study. Haematologica 2009; 94 (Suppl 2) Abstract 0231
  PubMedGoogle Scholar
• 89 Saleh MN, Cheng G, Bussel JB , et al. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) From June 2006 to February 2010. ASH Annual Meeting Abstracts 2010; 116 (21) 67
  PubMedGoogle Scholar
• 90 Yan XQ, Lacey D, Hill D , et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88 (2) 402-409
  PubMedGoogle Scholar
• 91 Kakumitsu H, Kamezaki K, Shimoda K , et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 2005; 29 (7) 761-769
  CrossrefPubMedGoogle Scholar
• 92 Villeval JL, Cohen-Solal K, Tulliez M , et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90 (11) 4369-4383
  PubMedGoogle Scholar
• 93 Pecquet C, Staerk J, Chaligné R , et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2010; 115 (5) 1037-1048
  CrossrefPubMedGoogle Scholar
• 94 Teofili L, Giona F, Torti L , et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 2010; 95 (1) 65-70
  CrossrefPubMedGoogle Scholar
• 95 Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114 (18) 3748-3756
  CrossrefPubMedGoogle Scholar
• 96 Saleh MN, Bussel JB, Meyer O , et al. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag. ASH Annual Meeting Abstracts 2009; 114 (22) 1326
  PubMedGoogle Scholar